Christian O. Henry - 11 Aug 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
Director
Signature
/s/ Christian Henry
Issuer symbol
WVE
Transactions as of
11 Aug 2025
Transactions value $
-$85,193
Form type
4
Filing time
13 Aug 2025, 20:00:08 UTC
Previous filing
13 Jun 2025
Next filing
10 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HENRY CHRISTIAN O Director C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Christian Henry 13 Aug 2025 0001263805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Award $0 +12.7K +47.72% $0.00 39.3K 11 Aug 2025 Direct F1
transaction WVE Ordinary Shares Sale -$85.2K -9.67K -24.6% $8.81 29.6K 13 Aug 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Award $0 +76.2K $0.00 76.2K 11 Aug 2025 Ordinary Shares 76.2K $8.11 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2024.
F3 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $8.45 to $9.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026